Loading...
XSTOMCAP
Market cap792mUSD
Dec 23, Last price  
591.00SEK
1D
-1.17%
1Q
22.23%
Jan 2017
1,603.17%
IPO
4,446.15%
Name

MedCap AB (publ)

Chart & Performance

D1W1MN
XSTO:MCAP chart
P/E
50.82
P/S
5.51
EPS
11.63
Div Yield, %
0.00%
Shrs. gr., 5y
2.04%
Rev. gr., 5y
17.49%
Revenues
1.59b
+42.83%
188,857,000187,055,000258,787,000315,887,000336,510,000349,041,000826,086,000852,754,000816,918,000851,668,000411,200,000709,000,000757,100,000817,400,000916,300,0001,111,400,0001,587,400,000
Net income
172m
+46.43%
-7,727,000114,0005,797,00013,511,00010,705,00017,112,00022,608,0008,524,00019,452,00073,0002,100,000600,00053,700,00060,900,00096,500,000117,600,000172,200,000
CFO
228m
+166.67%
2,146,0003,373,00017,317,00030,637,00028,749,00038,550,000865,0002,258,000-14,917,00081,456,00027,300,00090,600,00071,400,000115,600,000116,300,00085,500,000228,000,000
Earnings
Jan 31, 2025

Profile

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
URL
https://www.medcap.se/
IPO date
Jul 04, 2006
Employees
463
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑042016‑042015‑04
Income
Revenues
1,587,400
42.83%
1,111,400
21.29%
916,300
12.10%
Cost of revenue
675,500
683,000
678,500
Unusual Expense (Income)
NOPBT
911,900
428,400
237,800
NOPBT Margin
57.45%
38.55%
25.95%
Operating Taxes
49,800
34,000
18,900
Tax Rate
5.46%
7.94%
7.95%
NOPAT
862,100
394,400
218,900
Net income
172,200
46.43%
117,600
21.87%
96,500
58.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,800
(9,100)
1,100
BB yield
Debt
Debt current
69,000
116,100
91,500
Long-term debt
339,400
379,700
337,000
Deferred revenue
3,900
Other long-term liabilities
33,200
5,700
22,400
Net debt
219,800
259,400
288,400
Cash flow
Cash from operating activities
228,000
85,500
116,300
CAPEX
(22,100)
(44,300)
(60,900)
Cash from investing activities
(152,300)
(56,100)
(64,800)
Cash from financing activities
(119,700)
61,200
(64,100)
FCF
819,000
275,000
102,400
Balance
Cash
188,200
236,200
139,700
Long term investments
400
200
400
Excess cash
109,230
180,830
94,285
Stockholders' equity
598,800
430,400
269,800
Invested Capital
1,212,270
998,770
872,815
ROIC
77.98%
42.15%
26.67%
ROCE
65.69%
35.16%
23.66%
EV
Common stock shares outstanding
14,857
14,807
14,802
Price
Market cap
EV
EBITDA
1,015,900
516,200
313,300
EV/EBITDA
Interest
15,600
16,400
9,400
Interest/NOPBT
1.71%
3.83%
3.95%